Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Incidence of drug-induced liver injury 

A study in the latest issue of Gastroenterology examines the incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland.

News image

Little is known about the incidence of drug-induced liver injury in the general population.

Dr Einar Björnsson and colleagues from Iceland investigated the incidence, and the quantitative risk of drug-induced liver injury in a population-based cohort.

The research team performed a prospective study and collected data from 96 individuals diagnosed with drug-induced liver injury in Iceland from 2010 through 2011.

Liver injury was defined based on levels of alanine aminotransferase that were more than 3-fold the upper limit of normal, and/or alkaline phosphatase levels more than 2-fold the upper limit of normal.

Patients with acetaminophen toxicity were excluded.

The research team analyzed the drug history and clinical outcomes.

Drug-induced liver injury was caused by a single prescription medication in 75% of cases
Gastroenterology

Causality was assessed using the Roussel Uclaf Causality Assessment Method.

The patients were registered in prescription databases for outpatients and inpatients.

The crude annual incidence rate of drug-induced liver injury was 19 cases per 100,000 inhabitants.

The doctors found that drug-induced liver injury was caused by a single prescription medication in 75% of cases, by dietary supplements in 16% of cases, and by multiple agents in 9% of cases.

The most commonly implicated drugs were amoxicillin-clavulanate, diclofenac, azathioprine, infliximab, and nitrofurantoin.

The median duration of therapy was 20 days.

The team observed that 26 patients had jaundice, and 22 patients were hospitalized for a median of 5 days.

The researchers noted that overall 35,252 patients received amoxicillin-clavulanate as outpatients, and drug-induced liver injury occurred in 1 of 2350.

Drug-induced liver injury also occurred in 1 of 9480 patients taking diclofenac, 1 of 133 patients taking azathioprine, 1 of 148 patients taking infliximab, and 1 of 1369 patients taking nitrofurantoin.

Dr Björnsson's team commented, "In a population-based study in Iceland, the incidence of drug-induced liver injury was the highest reported to date."

"Amoxicillin-clavulanate was the most commonly implicated agent."

"The highest risk of hepatotoxicity was associated with azathioprine and infliximab, but the actual number of cases attributed to these agents was small."

Gastroenterol 2013: 144(7) :1419-1425
04 July 2013

Go to top of page Email this page Email this page to a colleague

 31 October 2014

Advanced search
 31 October 2014 
C. difficile infection with metronidazole
 31 October 2014 
Pediatric NAFLD
 31 October 2014 
Pregnancy complications in celiac disease
 30 October 2014 
Constipation and colorectal cancer
 30 October 2014 
Costs in newly diagnosed patients with chronic constipation
 30 October 2014 
Cirrhosis in women
 29 October 2014 
Quality of life after infection with E. coli
 29 October 2014 
IBS in primary care
 29 October 2014 
Sensorimotor activity in functional dyspepsia
 28 October 2014 
Risk factor for smaller final height in Crohn's
 28 October 2014 
Increased bile acid synthesis in IBS-diarrhea
 28 October 2014 
Successful radiofrequency ablation for Barrett’s
 27 October 2014 
Celiac disease and type 1 diabetes
 27 October 2014 
Gluten awareness among chefs
 27 October 2014 

PPI-responsive esophageal eosinophilia

 24 October 2014 
Olmesartan-associated enteropathy
 24 October 2014 
Opioid use in IBD
 24 October 2014 
NSAIDs and Barrett's risk
 23 October 2014 
Outcomes in hospitalized patients with GI bleeding
 23 October 2014 
Thiopurines and colorectal cancer risk in IBD
 23 October 2014 
Advancing the field of functional GI disorders
 22 October 2014 
Early-TIPSS placement prevents rebleeding
 22 October 2014 
Liver fibrosis prognostic biomarkers in type-2 diabetes
 22 October 2014 
H pylori eradication with multiple drug resistance
 21 October 2014 
Alcohol and Barrett's
 21 October 2014 
Scoring systems for critically ill cirrhotic patients
 21 October 2014 
Aspirin and NAFLD
 20 October 2014 
Adalimumab in secondary loss of response in Crohn's
 20 October 2014 
Drug resistant H pylori eradication
 20 October 2014 
Omega-3 and colorectal cancer
 17 October 2014 
Tumor necrosis factor-alpha inhibitors and pregnancy in IBD
 17 October 2014 
Colorectal testing utilization
 17 October 2014 
Fecal microbiota composition in postinfectious IBS
 16 October 2014 
Risk of Barrett's esophagus
 16 October 2014 
Aspirin tablets and colorectal tumours
 16 October 2014 
Economic impact of IBS
 15 October 2014 
Achieving competency at colonoscopy
 15 October 2014 
Preparation for surgery in Crohn's
 15 October 2014 
Bowel preparations
 14 October 2014 
Colorectal testing utilization in commercially insured US adults
 14 October 2014 
Sustained response to infliximab
 14 October 2014 
IBD management during pregnancy
 13 October 2014 
Predicting PPI response in GERD-related cough
 13 October 2014 
Probiotics in IBS
 13 October 2014 
Use of azathioprine in IBD
 10 October 2014 
NAFLD in the Veterans Administration population
 10 October 2014 
Liver injury from herbals and dietary supplements
 10 October 2014 
Predictors for cecal insertion time
 09 October 2014 
Methotrexate-related liver disease and metabolic syndrome
 09 October 2014 
Biomarkers of acetaminophen overdose patients
 09 October 2014 
Postoperative adhesions in digestive surgery
 08 October 2014 
Gluten introduction in high risk children
 08 October 2014 
Vitamin D and HCC
 08 October 2014 
Feeding intervention in celiac disease infants
 07 October 2014 
Infliximab in pediatric perianal Crohn's
 07 October 2014 
Omega-3 and NAFLD
 07 October 2014 
Endoscopic submucosal dissection in the colorectum 
 06 October 2014 
Clinical indications for computed tomographic colonography
 06 October 2014 
Certolizumab pegol in the treatment of Crohn's
 06 October 2014 
Costs of telaprevir therapy for Hep C

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us